186例儿童或先天性心脏病心脏移植分析:移植前心室辅助装置的影响
单中心回顾分析2011年1月1日至2022年3月1日181例儿童或先天性心脏病患者接受的186例心脏移植,评估移植前心室辅助装置(VAD)的影响。移植前VAD不影晌生存,多变量分析中VAD不是移植后死亡的危险因素。
要点
- 移植前VAD存在于186例移植中的53例(28.5%)。
- 有VAD患者较无VAD患者更年轻、既往心脏手术次数更多、更可能接受ABO不相容移植。
- 多变量分析中移植前VAD不影响生存,不是移植后死亡的危险因素。
核心结论
- 移植前VAD不是儿童或先天性心脏病心脏移植后死亡的危险因素。
- 有VAD(n=51)与无VAD(n=130)患者生存相似。
研究设计与样本
- 单中心回顾性分析,纳入2011年1月1日至2022年3月1日181例儿童或先天性心脏病患者接受的186例心脏移植。
- 连续变量以均值(标准差)、中位数[四分位距](范围)表示,分类变量以例数(百分比)表示。
- 采用Cox比例风险模型评估与长期死亡的单变量关联,多变量模型估计移植前VAD对生存的影响。
主要发现
- 移植前VAD存在于186例移植中的53例(28.5%)。
- 有VAD患者年龄(岁)为4.8(5.6);1[0.5-8](0.1-18) vs 无VAD患者12.1(12.7);10[0.7-17](0.1-58),P=.0001。
- 有VAD患者既往心脏手术次数为3.0(2.3);2[1-4](1-12) vs 无VAD患者1.8(1.9);2[0-3](0-8),P=.0003。
- 有VAD患者接受ABO不相容移植为10/53(18.9%) vs 无VAD患者9/133(6.8%),P=.028。
- Kaplan-Meier 5年生存(95%CI)全部患者为85.8%(80.0%-92.1%),无移植前VAD为84.3%(77.2%-92.0%),有移植前VAD为91.1%(83.1%-99.9%)。
临床怎么用
- 原文未据此给出推荐。
- 作者结论认为移植前VAD不是儿童或先天性心脏病心脏移植后死亡的危险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We reviewed our management strategy and outcome data for all 181 patients with pediatric or congenital heart disease who received 186 heart transplants from January 1, 2011, to March 1, 2022, and evaluated the impact of pretransplant ventricular assist device (VAD). METHODS: Continuous variables are presented as mean (SD); median [interquartile range] (range). Categorical variables are presented as number (percentage). Univariable associations with long-term mortality were assessed with Cox proportional hazards models. Impact of pretransplant VAD on survival was estimated with multivariable models. RESULTS: Pretransplant VAD was present in 53 of 186 transplants (28.5%). Patients with VAD were younger (years): 4.8 (5.6); 1 [0.5-8] (0.1-18) vs 12.1 (12.7); 10 [0.7-17] (0.1-58); P = .0001. Patients with VAD had a higher number of prior cardiac operations: 3.0 (2.3); 2 [1-4] (1-12) vs 1.8 (1.9); 2 [0-3] (0-8); P = .0003. Patients with VAD were also more likely to receive an ABO-incompatible transplant: 10 of 53 (18.9%) vs 9 of 133 (6.8%); P = .028. Univariable associations with long-term mortality included: In multivariable analysis, pretransplant VAD did not impact survival while controlling for each one of the factors shown in univariable analysis to be associated with long-term mortality. Kaplan-Meier 5-year survival (95% CI) was 85.8% (80.0%-92.1%) for all patients, 84.3% (77.2%-92.0%) without pretransplant VAD, and 91.1% (83.1%-99.9%) with pretransplant VAD. CONCLUSIONS: Our single-institution analysis of 181 patients receiving 186 heart transplants for pediatric or congenital heart disease over 11.25 years reveals similar survival in patients with (n = 51) and without (n = 130) pretransplant VAD. The presence of a pretransplant VAD is not a risk factor for mortality after transplantation for pediatric or congenital heart disease.
引用
- Bleiweis MS, Stukov Y, Sharaf OM, et al. An Analysis of 186 Transplants for Pediatric or Congenital Heart Disease: Impact of Pretransplant VAD. Ann Thorac Surg. 2023. PMID: 37094611. doi:10.1016/j.athoracsur.2023.02.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。